Theralase Achieves Exploratory Endpoint of Efficacy for Anti-Cancer Technology

Theralase Technologies (TSXV:TLT; OTCQX:TLTFF) announced the recommended starting dose for its lead compound TLD-1433 at a 90-day cystoscopy analysis achieved exploratory endpoint of efficacy in patients inflicted with Non-Muscle Invasive Bladder Cancer.
As quoted in the press release:

These three patients come from a population that has failed standard of care and have remained drug resistant after the standard first line Bacillus Calmette Guérin (“BCG“) course of treatments.
The exploratory efficacy endpoint is being reported at ninety (90) days, in the first 3 patients treated, in the first part of a Phase Ib clinical study (“Study).
The Study is entitled “A Phase Ib Trial of Intravesical Photodynamic Therapy in Patients with Non-Muscle Invasive Bladder Cancer at High Risk of Progression Who are Refractory to Therapy with Bacillus Calmette-Guérin (“BCG“) and Who are Medically Unfit for or Refuse a Cystectomy.
The Study is being used to evaluate TLD-1433 for the: primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy.

Click here to read the full press release.

Source: www.accesswire.com